FDA reverses course, will review Moderna’s mRNA flu vaccine candidate

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu vaccine candidate after holding a high-priority meeting with the company. Last week, the FDA said it refused to file Moderna’s application over regulatory issues. The company maintained that the refusal had nothing to do with…